Isoproterenol-induced FKBP12.6/12 downregulation is modulated by ET A and ETB receptors and reversed by argirhein, a derivative of rhein

Acta Pharmacologica Sinica

Volumn 32, Issue 2, 2011, Pages 223-229

  Zhang, Guo Lin ^a   Dai, De Zai ^a   Xi, Tao ^a   Cong, Xiao Dong ^b   Zhang, Yun ^b   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

argirhein; ETA receptor; ETB receptor; FKBP12.6 12; isoproterenol; rhein

Indexed keywords

4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; ARGIRHEIN; CPU 0213; ENDOTHELIN 1 [11-21]; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12.6; ISOPRENALINE; MESSENGER RNA; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HEART MUSCLE CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ISOPROTERENOL; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TACROLIMUS BINDING PROTEIN 1A; TACROLIMUS BINDING PROTEINS;

EID: 79551660035     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.177     Document Type: Article

References (38)

1. Sen-Chowdhry S, McKenna WJ. Sudden cardiac death in the young: A strategy for prevention by targeted evaluation. Cardiology 2006; 105: 196-206.
2. Gollob MH. Genetic profiling as a marker for risk of sudden cardiac death. Curr Opin Cardiol 2006; 21: 42-6.
3. Chow BJ, Gollob M, Birnie D. Brugada syndrome precipitated by a tricyclic antidepressant. Heart 2005; 91: 651.
4. Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003; 113: 829-40.
5. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004; 95: 754-63.
6. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J ClinInvest 2005; 115: 2305-15.
7. Blum A: Heart failure-new insights. Isr Med Assoc J 2009; 11: 105-11.
8. Yano M, Yamamoto T, Ikeda Y, Matsuzaki M. Mechanisms of disease: ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Pract Cardiovasc Med 2006; 3: 43-52.
9. Blayney LM, Jones JL, Griffiths J, Lai FA. A mechanism of ryanodine receptor modulation by FKBP12/12.6, protein kinase A, and K201. Cardiovasc Res 2010; 85: 68-78.
10. Jiang D, Jones PP, Davis DR, Gow R, Green MS, Birnie DH, et al. Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia. Channels (Austin) 2010; 4; 302-10.
11. Li N, Jia N, Dai DZ, Hu C, Dai Y. Role of endothelin in the effects of isoprenaline on potassium currents and calsequestrin 2 expression in the heart. Clin Exp Pharmacol Physiol 2010; 37: 557-63.
12. Zhang Y, Huang ZJ, Dai DZ, Feng Y, Na T, Tang XY, et al. Downregulated FKBP12.6 expression and upregulated endothelin signaling contribute to elevated diastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by l-thyroxin. Int J Cardiol 2008; 130: 463-71.
13. Györke S, Carnes C. Dysregulated sarcoplasmic reticulum calcium release: potential pharmacological target in cardiac disease. Pharmacol Ther 2008; 119: 340-54.
14. Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther 2005; 315: 1058-64.
15. Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 2006; 47: 222-9.
16. Guo MZ, Li XS, Xu HR, Mei ZC, Shen W, Ye XF. Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol Sin 2002; 23: 739-44.
17. Malaguti C, Vilella CA, Vieira KP, Souza GH, Hyslop S, Zollner Rde L. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol 2008; 8: 782-91.
18. Peng HJ, Dai DZ, Ji H, Dai Y. The separate roles of endothelin receptors participate in remodeling of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in maladaptive response to isoproterenol. Eur J Pharmacol 2010; 634: 101-6.
19. Feng Y, Tang XY, Dai DZ, Dai Y. Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213- mediated antagonism of endothelin receptors. Acta Pharmacol Sin 2007; 28: 1746-54.
20. Chelu MG, Wehrens XH. Sarcoplasmic reticulum calcium leak and cardiac arrhythmias. Biochem Soc Trans 2007; 35: 952-6.
21. Huang F, Shan J, Reiken S, Wehrens XH, Marks AR. Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of heart failure by calstabin2 in mice. Proc Natl Acad Sci USA 2006; 103: 3456-61.
22. Cheng YS, Dai DZ, Dai Y. Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin. J Pharm Pharmacol 2009; 61: 569-76.
23. 2+ leak in failing hearts. Cardiovasc Res 2009; 81: 536-45.
24. Qi MY, Feng Y, Dai DZ, Li N, Cheng YS, Dai Y. CPU86017, a berberine derivative, attenuates cardiac failure through normalizing calcium leakage and downregulated phospholamban and exerting antioxidant activity. Acta Pharmacol Sin 2010; 31: 165-74.
25. Na T, Dai DZ, Tang XY, Dai Y. Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 39-49.
26. Isaka M, Kudo A, Imamura M, Kawakami H, Yasuda K. Endothelin receptors, localized in sympathetic nerve terminals of the heart, modulate norepinephrine release and reperfusion arrhythmias. Basic Res Cardiol 2007; 102: 154-62.
27. Zheng JM, Zhu JM, Li LS, Liu ZH. Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway. Br J Pharmacol 2008; 153: 1456-64.
28. Gao Q, Qin WS, Jia ZH, Zheng JM, Zeng CH, Li LS, et al. Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy. Planta Med 2010; 76: 27-33.
29. Jia ZH, Liu ZH, Zheng JM, Zeng CH, Li LS. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice. Exp Clin Endocrinol Diabetes 2007; 115: 571-6.
30. Legendre F, Heuze A, Boukerrouche K, Leclercq S, Boumediene K, Galera P, et al. Rhein, the metabolite of diacerhein, reduces the proliferation of osteoarthritic chondrocytes and synoviocytes without inducing apoptosis. Scand J Rheumatol 2009; 38: 104-11.
31. Boileau C, Tat SK, Pelletier JP, Cheng S, Martel-Pelletier J. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther 2008; 10: R71.
32. Malaguti C, Vilella CA, Vieira KP, Souza GH, Hyslop S, Zollner Rde L. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol 2008; 8: 782-91.
33. Legendre F, Bogdanowicz P, Martin G, Domagala F, Leclercq S, Pujol JP, et al. Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin Exp Rheumatol 2007; 25: 546-55.
34. Li N, Jia N, Dai DZ, Dai Y. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon. Eur J Pharmacol 2008; 591: 211-8.
35. Xia HJ, Dai DZ, Dai Y. Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats. Life Sci 2006; 79: 1812-9.
36. Du RH, Yi HW, Dai DZ, Tang WH, Dai Y. Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent. J Pharm Pharmacol 2008; 60: 1089-95.
37. Altamirano E, Drut R. Arrhythmogenic cardiomyopathy in a patient with Noonan syndrome. Fetal Pediatr Pathol 2010; 29: 158-64.
38. Zumhagen S, Spieker T, Rolinck J, Baba HA, Breithardt G, Böcker W, et al. Absence of pathognomonic or inflammatory patterns in cardiac biopsies from patients with Brugada syndrome. Circ Arrhythm Electrophysiol 2009; 2: 16-23.